Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthritis, who had been previously treated with rituximab at the standard dose for at least two cycles obtaining a good clinical response [Valutazione di efficacia di Rituximab al dosaggio di 500mg e.v., 2 infusioni a distanza di 2 settimane, in confronto al dosaggio standard di 1000mg e.v., 2 infusioni a distanza di 2 settimane nel mantenimento della buona risposta clinica in pazienti affetti da artrite reumatoide, gia trattati con Rituximab al dosaggio standard per almeno 2 cicli]

Next Previous
X
Search
Trial Profile

Efficacy of rituximab at the dose of 500 mg e.v., two infusions two weeks apart, versus rituximab at the usual dose of 1000 mg, two infusions two weeks apart, in patients affected by rheumatoid arthritis, who had been previously treated with rituximab at the standard dose for at least two cycles obtaining a good clinical response [Valutazione di efficacia di Rituximab al dosaggio di 500mg e.v., 2 infusioni a distanza di 2 settimane, in confronto al dosaggio standard di 1000mg e.v., 2 infusioni a distanza di 2 settimane nel mantenimento della buona risposta clinica in pazienti affetti da artrite reumatoide, gia trattati con Rituximab al dosaggio standard per almeno 2 cicli]

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 Sep 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top